<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>In this retrospective study, 61 induction treatment periods in 57 patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) or <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) were evaluated </plain></SENT>
<SENT sid="1" pm="."><plain>According to the WHO performance status, 6 patients received no chemotherapy, 20 had low dose <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> (LD ara-C) induction courses, and 35 received standard induction consisting of <z:chebi fb="0" ids="41977">daunorubicin</z:chebi> and <z:chebi fb="1" ids="16040">cytosine</z:chebi> <z:chebi fb="0" ids="22601">arabinoside</z:chebi> </plain></SENT>
<SENT sid="2" pm="."><plain>Untreated patients had a poor survival </plain></SENT>
<SENT sid="3" pm="."><plain>Of the 20 patients with LD ara-C induction courses, 4 (20%) achieved complete remission (CR) </plain></SENT>
<SENT sid="4" pm="."><plain>Three patients (15%) died during induction </plain></SENT>
<SENT sid="5" pm="."><plain>Of 35 patients with standard induction, 21 patients (60%) achieved CR </plain></SENT>
<SENT sid="6" pm="."><plain>Toxicity was considerable - 11 patients (31%) dying during treatment </plain></SENT>
<SENT sid="7" pm="."><plain>We conclude that patients over 60 yr of age with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">RAEB</z:e>-t or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> had a CR rate and survival comparable to those of younger patients if treated with standard induction chemotherapy at the cost of serious therapy-related complications </plain></SENT>
<SENT sid="8" pm="."><plain>In patients who were judged not to be able to tolerate standard induction and who were subsequently treated with LD ara-C, complications occurred less frequently, but the CR rate was low and survival short </plain></SENT>
</text></document>